ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Nipecotic Acid Ameliorates Letrozole Induced Poly Cystic Ovarian Syndrome in Female Virgin Wistar Rats by Modulating Hypothalamic-Pituitary-Gonadal (HPG) Axis Regulated by GABA.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PCOS is a common endocrine disorder in women particularly in their reproductive age. GABA has been implicated in the pathogenesis of PCOS through its central role in the hypothalamus. Hence, in this study we investigated the effect of Nipecotic acid (NPA) in Letrozole induced PCOS in female Wistar rats as NPA has been proven as a GABA uptake inhibitor. In this study 30 female Wistar rats were divided into 5 groups each group containing 6 animals and treated as follows-Healthy control: Vehicle, 0.5% carboxymethylcellulose (CMC); Diseased control: Letrozole 1 mg/kg orally in 0.5% CMC; Test group-1: Letrozole + NPA (2.5 mg/kg i.p.); Test group-2: Letrozole + NPA (5 mg/kg i.p.) and Standard group: Letrozole + Clomiphene citrate (1 mg/kg in 0.5% CMC orally). Body weight, feed intake, water intake and vaginal smear was recorded on daily basis till the completion of the treatment tenure, whereas serum oestrogen, testosterone and GABA; ovary and uterus histopathology; lipid profile; OGTT; GsH, MDA and TNF-alpha in ovary tissue were estimated in the end of the treatment tenure. NPA treated groups demonstrated an improvement in the irregularities of the oestrous cycle with respect to PCOS control group. Further, NPA at both doses significantly (p < 0.001) reduced oxidative stress and inflammation in the ovary. It significantly (p < 0.001) reduced the serum testosterone and significantly (p < 0.001) elevated the serum oestrogen level. Histopathological reports depicted NPA reduced follicular cysts and promoted ovulation. These results emphasize the possibility of NPA as a treatment option for PCOS related reproductive and metabolic disorders, addressing the unmet need for effective PCOS management.
Indexed as
Identifiers
39794617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.